Clinical Trials Logo

Parkinson Disease clinical trials

View clinical trials related to Parkinson Disease.

Filter by:

NCT ID: NCT03841604 Not yet recruiting - Clinical trials for Idiopathic Parkinson Disease

Effect of Safinamide on Parkinson's Disease Related Chronic Pain

Start date: February 28, 2019
Phase: Phase 4
Study type: Interventional

This is a Phase IV, international, multicentre, randomised, double-blind, placebo controlled study in IPD patients, experiencing motor fluctuations and PD related chronic pain while on stable doses of levodopa (L-Dopa). Participants will be randomized 2:1 to receive either active or placebo

NCT ID: NCT03840837 Not yet recruiting - Parkinson Disease Clinical Trials

Cholinergic Neurotransmission in Mobility and Cognition in Parkinson Disease

Start date: March 2019
Phase: Phase 4
Study type: Interventional

This is a single-site, single-group open label 3-month pilot study. The investigators will use accelerometer-based instrumented gait analysis and computerized cognitive testing to study the interaction of motor and cognitive dysfunction in Parkinson disease dementia (PDD). Study participants will be treated with rivastigmine for 12 weeks, and the effect of this treatment on gait measures and cognitive measures will be analyzed. Specifically, we will determine which components of motor and cognitive impairment are associated with each other, and which components of the two domains respond to rivastigmine-mediated stimulation of cholinergic neurotransmission.

NCT ID: NCT03840252 Recruiting - Clinical trials for Parkinson Disease (PD)

Progression of Striatal and Extrastriatal Degeneration in PD and PSP Patients

Start date: September 23, 2015
Study type: Observational

This project aims to study the PD and PSP patients with fMRI and DTI in order to investigate whether diffusion and functional connectivity are modified in PD and PSP patients compared to HC and whether diffusion and functional connectivity alterations are correlated with gait impairments and clinical disease severity scores in PD and PSP patients. The current study proposed to investigate the following issues: - Evaluation of differences in whole-brain and extra striatal regions connectivity in PD and PSP patients compared to HC. - Evaluation of possible changes in brain connectivity over a period of 18 months in PD and PSP patients compared to HC. - Evaluation of the presence and possible evolution over a period of 18 months of microstructural alterations in PD and PSP patients compared to HC with the auxiliary of DTI. - to analyze whether diffusion and resting-state functional connectivity are correlated with clinical disease severity scores and how they change over the time (18 months later). - to perform a multifactorial quantitative analysis of outcomes for PD and PSP compared to a control group in order to categorize the gait in the group of patients and verify if the gait can be useful as discriminator for diagnosis.

NCT ID: NCT03840005 Recruiting - Parkinson's Disease Clinical Trials

Trial of Ursodeoxycholic Acid (UDCA) for Parkinson's Disease: The "UP" Study

Start date: December 18, 2018
Phase: Phase 2
Study type: Interventional

The aim of this study is to explore the potential of Ursodeoxycholic acid (UDCA) to slow down the progression of Parkinson's Disease (PD) in a randomised, double-blind, placebo-controlled, "proof of concept" study. The primary objective of the study will be to determine the safety and tolerability of this drug in patients with PD. Participants will be recruited form a cohort of patients who have been diagnosed with PD within the last 3 years and are potentially suitable for this study. There is strong evidence from previous research and the work carried out by other groups that UDCA rescues the function of the mitochondria (mitochondria are the "powerhouse" of the cell) in PD patient tissue and other models of PD. This suggests that UDCA may slow down the worsening of PD. UDCA has been in clinical use for the treatment of liver disease (primary biliary cholangitis) for over 30 years. We therefore know that it is safe and well tolerated in patients with liver disease but we don't know yet whether this is also the case in patients with PD. Furthermore, the dose used for patients with liver disease (15 mg/kg) is not high enough for UDCA to get into the brain. We therefore need to double the dose to 30 mg/kg. This higher dose was also safe in clinical trials for liver disease, but is currently not used routinely in clinical practice.

NCT ID: NCT03839381 Not yet recruiting - Multiple Sclerosis Clinical Trials

Turkish Version of Mini-BESTest, Validity and Reliability for Adult Participants With Sensoriomotor Impairments

Start date: March 4, 2019
Study type: Observational

The aim of this study is to present the Turkish version of miniBESTest which evaluates the reasons of balance deficit and postural control. Accordingly, a practice of validity and reliability on adult patients with sensoriomotor impairments will be performed by utilizing the Turkish version of miniBESTest in this study.

NCT ID: NCT03837548 Recruiting - Parkinson Disease Clinical Trials

A Study of Neurofeedback for the Treatment of Parkinson's Disease

Start date: March 1, 2019
Phase: N/A
Study type: Interventional

This study aims to reveal relationship between brain activities and the symptoms of Parkinson disease when a neurofeedback training was applied for them.

NCT ID: NCT03837314 Not yet recruiting - Parkinson's Disease Clinical Trials

Simpler and Safer Deep Brain Stimulation for Parkinson's Disease

Start date: February 1, 2019
Phase: N/A
Study type: Interventional

The aim is to improve availability and acceptability of deep brain stimulation (DBS) for the treatment of Parkinson by shortening and simplifying the implantation procedure, thereby reducing time in surgery, complexity, post-surgery complications and cost, and increasing patient satisfaction. To facilitate the shortening and simplifying of the implantation procedure, a miniaturised skull-mounted DBS device (Picostim) has been developed which is optimised to generate waveforms needed for stimulation of the subthalamic nucleus (STN) and STN region, employing a unique method of controlling stimulation current. The planned study is a single centre, open label, non-randomised design with the primary objective of showing similarity in control of motor symptoms for the Picostim device compared with previously published data for existing DBS devices.

NCT ID: NCT03837067 Recruiting - Parkinson's Disease Clinical Trials

Use and Misuse of Domperidone in Parkinson's Disease in France - Dump Investigation

Start date: July 17, 2018
Study type: Observational

Parkinson disease is the second most frequent neurodegenerative disease after Alzheimer disease and affect 1% of the population over 60 years. The treatment of PD is based on dopamine replacement therapies (DRT). Nausea is the most frequent adverse event whatever the drug, occurring in 30-40% of patients at the initiation of DRT. Domperidone, a dopamine D2 receptor antagonist with antiemetic properties, does not readily cross the blood-brain barrier, allowing its used in PD. Domperidone may prolong the duration of the QT interval in predisposed patients, and has been associated with proarrhythmia and arrhythmic deaths. Arrhythmias, sudden death and cardiac arrest were reported with high intravenous doses which has led to withdraw of the parenteral form of the drug in 1984. Two case control studies found an increased risk of sudden death associated with domperidone use. In these reports, the increased risk was depending on age, dose, and the use of domperidone in combination with CYP3A4 inhibitors. Following the discussion created by this alert, the PRAC of the EMA has issued recommendations restricting domperidone use to patients younger than 60 years at doses below 30 mg/day and for a short period (7 days). Because there is no alternative antiemetic drug to be used in PD, domperidone is commonly prescribed as a preventive therapy in most PD patients initiating DRT. In this population, usually older than 60 years, doses of 60 or 80 mg/day are commonly prescribed, for at least 2 months of the DRT escalating dose period or longer. A particular "niche" of domperidone misuse might be patients treated with continuous subcutaneous administration of apomorphine, a second line therapy in PD, inducing severe and prolonged nausea in almost all patients. Little is known about the use of domperidone in PD in France, but misuse of domperidone in PD patients is probably very high. Data collected from two French PD cohorts, COPARK and DIGPD, showed that 8-14% of PD patients were treated with domperidone. The aim of this proposal is to investigate the practices and beliefs of French neurologists regarding use and misuse of domperidone in PD, by a qualitative approach.

NCT ID: NCT03836963 Not yet recruiting - Parkinson's Disease Clinical Trials

Cognitive Rehab for Parkinson's

Start date: September 16, 2019
Phase: N/A
Study type: Interventional

This study will examine the feasibility of an at-home cognitive training program that incorporates both memory training and online computerized cognitive training (CCT) software. Data will also be collected to determine if this program improves thinking and memory as well as everyday function. The hypothesis is that memory and cognitive training combined , compared to memory training alone or will lead to greater improvements in cognitive performance and daily function.

NCT ID: NCT03836950 Not yet recruiting - Parkinson's Disease Clinical Trials

rTMS to Improve Cognition in Parkinson's

Start date: June 28, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to examine safety, feasibility, and the behavioral and brain effects of a non-invasive treatment, repetitive transcranial magnetic stimulation (rTMS), for Veterans with Parkinson's disease and mild impairments in their thinking. The hypothesis is that rTMS can improve thinking for people with Parkinson's disease who are experiencing mild problems with their thinking ability.